Retrospective study assesses delay in sputum conversion for tuberculosis in diabetes patients, indicating glycemic control significance.
Background: The coexistence of tuberculosis (TB) and type 2 diabetes mellitus (T2DM) presents a significant clinical challenge. Hyperglycemia impairs immune function, contributing to delayed sputum conversion and increased morbidity. To analyze the clinico-investigative profile of TB in patients with T2DM and assess the im Objectives: pact of glycemic control on sputum conversion and treatment outcomes. A retrospective observational study wa Methods: s conducted on 15 patients with pulmonary TB and T2DM from August 2024 to January 2025. Clinical presentation, glycemic indices (HbA1c, FBS), imaging findings, anti-diabetic therapy, and sputum conversion time were evaluated. Results: Nine patients (60%) had delayed sputum conversion (≥3 months); all had HbA1c >9%. Ten patients (67%) required insulin therapy. FBS >200 mg/dL was strongly associated with prolonged treatment. One patient with MDR-TB and HbA1c of 12.3% died during therapy. Poor glycemic control (HbA1c >9%) correlates with delayed Conclusion: sputum conversion and adverse outcomes. Insulin therapy was beneficial. Integrating diabetes management into TB care protocols is essential.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: